Machine Learning models for the accurate prediction of malignant pheochromocytomas and paragangliomas: (Conference Presentation)

Research output: Contribution to journalConference articleContributed

Contributors

  • Christina Pamporaki - , Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden (Author)
  • Annika MA Berends - , University Medical Center Groningen (Author)
  • Angelos Filippatos - , Grand Challenge Lab Dresden Centre for Smart Materials, Institute of Lightweight Engineering and Polymer Technology (Author)
  • Tamara Prodanov - , National Institutes of Health (NIH) (Author)
  • Leah Meuter - , National Institutes of Health (NIH) (Author)
  • Aleksander Prejbisz - , National Institute of Cardiology, Warszawa (Author)
  • Felix Beuschlein - , University Hospital Zurich (Author)
  • Martin Fassnacht - , University Hospital of Würzburg (Author)
  • Henri Timmers - , Radboud University Medical Center (Author)
  • Svenja Noelting - , University Hospital Zurich (Author)
  • Kaushik Ganesh Abhyankar - , Institute of Lightweight Engineering and Polymer Technology (Author)
  • Georgiana Constantinescu - , Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden (Author)
  • Carola Kunath - , University Hospital Carl Gustav Carus Dresden (Author)
  • Katharina Wang - , University Hospital Zurich (Author)
  • Hanna Remde - , University Hospital of Würzburg (Author)
  • Andrzej Januszewicz - , National Institute of Cardiology, Warszawa (Author)
  • Mercedes Robledo - , Spanish National Cancer Research Center, Madrid (Author)
  • Jacques Lenders - , Radboud University Medical Center (Author)
  • Michiel Kerstens - , University Medical Center Groningen (Author)
  • Karel Pacak - , National Institutes of Health (NIH) (Author)
  • Graeme Eisenhofer - , Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus Dresden (Author)

Abstract

Introduction: Pheochromocytomas and paragangliomas (PPGLs) exhibit an up to 20% malignancy rate. Various clinical, genetic, and pathological features have been proposed as predictors of malignancy. However, until present there are no robust indices to reliably predict metastatic PPGLs.

Aim: The aim of the present study was to prospectively validate the value of methoxytyramine as risk marker of metastatic disease and establish a machine learning (ML) model, based on clinical and biochemical features, to reliably predict malignancy in patients with PPGLs.

Methods: This study included retrospective data of 493 patients for the generation and training of ML models. Data of 295 patients prospectively enrolled in the multicenter international PMT-Study were used for the validation of the predictive value of methoxytyramine and the external validation of the selected ML model. The predefined features for selection analysis were sex, age at initial diagnosis, locations and size of tumor(s), previous history of PPGL, presence of SDHB mutation, plasma normetanephrine, metanephrine and methoxytyramine.

Results: Receiver operating characteristic curves indicated that plasma methoxytyramine using an optimal cutoff of 33 pg/ml provided an accurate biomarker for detecting patients with metastatic PPGLs. After feature selection and the use of 4 different models, ensemble trees model, which comprised 9 features, had the greatest discriminatory ability with an AUC of 0.9938 (95% CI:0.9903-0.9951). The ensemble trees model was validated externally and ranked based on the balanced accuracy with an AUC of approximately 0.9261 (95% CI:0.9293-0.9381).

Conclusion: Our study confirms in a prospective series the value of methoxytyramine as a strong predictor of metastatic PPGLs. Importantly we demonstrate predictive ML models, as the first effective, non-invasive and highly accurate approach to predict malignant disease in patients with PPGLs, providing immediate guidance to clinicians for individualized patient management and follow-up strategies.

Details

Original languageEnglish
Article numberOC13.6
JournalEndocrine Abstracts
Volume2022
Issue number81
Publication statusPublished - 7 May 2022
Peer-reviewedNo

Conference

TitleCongress of Endocrinology 2022
Conference number
Duration21 - 24 May 2022
Location
CityMilan
CountryItaly

External IDs

Mendeley b6cc4e56-4a91-3158-9d59-3cef0d2eb560
ORCID /0000-0003-0311-1745/work/142241461

Keywords